The primary objective of the study is to assess whether a 6-week titration (compared with a
1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF
[Tecfidera])-related gastrointestinal (GI) adverse events (AEs) in participants with multiple
sclerosis (MS). The secondary objective of this study is to assess whether a 6-week titration
(compared with a 1-week titration) is effective in reducing the average severity and duration
of GI symptoms over 12 weeks of DMF treatment in this study population.